Form 10-K ACADIA PHARMACEUTICALS For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Acadia Pharma (ACAD) Misses Q4 EPS by 7c
February 29, 2016 9:19 AM ESTAcadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.45), $0.07 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $17 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More